Cargando…
Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial
Oral melphalan and prednisone remain an effective and tolerable treatment for patients with multiple myeloma. For approximately 40 years, this combination has been the standard of care for patients not proceeding to stem cell transplant. Within the last 10 years, new agents have been found to be eff...
| Autores principales: | , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Multimed Inc.
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891198/ https://www.ncbi.nlm.nih.gov/pubmed/17576467 |